Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Purpose: FAPI ligands (fibroblast activation protein inhibitor), a novel class of radiotracers for PET/CT imaging, demonstrated in previous studies rapid and high tumor uptake. The purpose of this study is the head-to-head intra-individual comparison of 68 Ga-FAPI versus standard-of-care 18 F-FDG in PET/CT in organ biodistribution and tumor uptake in patients with various cancers. Material and Methods: This international retrospective multicenter analysis included PET/CT data from 71 patients from 6 centers who underwent both 68 Ga-FAPI and 18 F-FDG PET/CT within a median time interval of 10 days (range 1–89 days). Volumes of interest (VOIs) were manually drawn in normal organs and tumor lesions to quantify tracer uptake by SUVmax and SUVmean. Furthermore, tumor-to-background ratios (TBR) were generated (SUVmax tumor/ SUVmax organ). Results: A total of 71 patients were studied of, which 28 were female and 43 male (median age 60). In 41 of 71 patients, the primary tumor was present. Forty-three of 71 patients exhibited 162 metastatic lesions. 68 Ga-FAPI uptake in primary tumors and metastases was comparable to 18 F-FDG in most cases. The SUVmax was significantly lower for 68 Ga-FAPI than 18 F-FDG in background tissues such as the brain, oral mucosa, myocardium, blood pool, liver, pancreas, and colon. Thus, 68 Ga-FAPI TBRs were significantly higher than 18 F-FDG TBRs in some sites, including liver and bone metastases. Conclusion: Quantitative tumor uptake is comparable between 68 Ga-FAPI and 18 F-FDG, but lower background uptake in most normal organs results in equal or higher TBRs for 68 Ga-FAPI. Thus, 68 Ga-FAPI PET/CT may yield improved diagnostic information in various cancers and especially in tumor locations with high physiological 18 F-FDG uptake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
Cited by
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Glabman, R. A., Choyke, P. L., & Sato, N. (2022) · Cancers · doi:10.3390/cancers14163906 · Cited by 254
Characterization of the benign lesions with increased 68Ga-FAPI-04 uptake in PET/CT
Zheng, S., Lin, R., Chen, S., Zheng, J., Lin, Z., Zhang, Y., Xue, Q., Chen, Y., Zhang, J., Lin, K., et al. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01673-w · Cited by 62
“which may affect their possible therapeutic significance [38, 39].”
Background
Metadata
- Authors
- Giesel, F. L., Kratochwil, C., Schlittenhardt, J., Dendl, K., Eiber, M., Staudinger, F., Kessler, L., Fendler, W. P., Lindner, T., Koerber, S. A., Cardinale, J., Sennung, D., Roehrich, M., Debus, J., Sathekge, M., Haberkorn, U., Calais, J., Serfling, S., & Buck, A. L.
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2021-06-17
- Volume
- 48
- Issue
- 13
- Pages
- 4377-4385
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- OpenAlex
- W3167710775
- Cited by
- 219
- References
- 1
- FWCI
- 12.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.